Due to the role of PRL-3 in cancer progress, multiple drugs have been screened that can inhibit PRL-3 at the molecular level, effectively impeding the activity of PRL-3 in vivo and in vitro (Table 1). This evidence concerns the gene PTP4A3 and cancer.